Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To avoid any doubt ... and ignore false posts: No lawyer was added to the case.
Oliver Richards's Entry of Appearance was filed on April 21 (Doc 7). Doc 60 was filed due to change of his address ...
Doc 7: 12390 El Camino Real, Suite 100, San Diego, CA 92130
Doc 60: 12860 El Camino Real, Ste. 400, San Diego, CA 92130
Best,
G
Case 3:20-cv-00421; Document 1; Filed 07/13/20
Nothing burger ...
On information and belief, and as stated in a letter dated June 1, 2020 sent by Defendants to Amarin (the “June Notice Letter”), Defendants prepared and filed patent certifications with the FDA in support of amended ANDA No. 209457 with the intention of seeking to market a generic version of the 0.5 gram strength of Amarin’s VASCEPA® product (“generic VASCEPA® 0.5 g product”), including within this judicial district. Amarin received the June Notice Letter on June 2, 2020.
i-
If a settlement is to be reached, the lower court decision has to be vacated
B-
Was there an update reported recently?
B-
Or PR on Evaporate interim results?
p-
I know this is one of your areas of expertise
remaining shares from old program at 15.15 million shares
entire pool of equity awards to be worth $95.15 million, of which $15.15 million are shares remaining in the old plan
p-
Is that 20 million new shares added to the 15.15 or 4.85million added to the 15.15 for a grand total of 20 million?
The new plan includes 20 million shares that may be awarded as "stock options (both incentive and non-qualified stock options), restricted stock units and certain limited unrestricted share awards." Including shares remaining in the 2011 plan, the company valued the entire pool of equity awards to be worth $95.15 million, of which $15.15 million are shares remaining in the old plan.
f-
Today's post quantified the percentage reductions in plaque volume progression with V which was not included in the July 1 report.
JL-
It might be a rare case of Hungarian COVID brain fever
Where / when? I am not aware of a single document that contains anything similar to this ...
Judge Du did say that the generics should be careful in their marketing and actions less they be inducing infringement on Amarin's Non Marine patents which she did not invalidate
no recall of Du stating that the generics would be guilty of indirect infringement of Amarin's patents by "inducement"
M-
That gross revenue was calculated in generics prices or brand V prices ?
If V then ?
H-
Thx. Agree.
Best,
G
JL-
Judge Du did say that the generics should be careful in their marketing and actions less they be inducing infringement on Amarin's Non Marine patents which she did not invalidate
We had a great deal of discussion on this subject on this very board.
This included some remarks one of the companies (Hikma I think) made at an investor conference that suggested patient numbers that were considerably higher than the totals for the Marine indications..And this was thought to suggest H was aiming for more than the MARINE population..
C-
The only way out of this is for amarin to sue insurance companies. I am not sure how realistic is that.
JL-
I think the Marine win is worthless and there is no way the generics can shoehorn their way into the R-IT indication...Not unless they can get Du's infringement opinion reversed
why H and R have not moved forward in sell for the MARINE indication..
N-
Half of Hikma's exclusivity period is gone
Not sure what value our reduce-it exclusivity has in the real world. Technically we have it but the carve out rules would seem to make it meaningless.
s-
September 2020, which would be the earliest sitting
C-
Seems like a pretty terrible business decision if they decided to not monetize shareholder value now in Q3 with a partnership in Europe or hybrid approach like they have been saying
C-
Can anything in your opinion change this or cause Amarin to push off this estimated timeline?
At this stage is it possible for them to push off EU decision until after court verdict?
i-
let's be cognizant, that we're not missing the economics involved in the equation
W-
Still I am surprised that Du or district judges are able to review the settlement documents
Mandatory settlement conferences for patent cases must be conducted by the magistrate judge assigned to the case
Unless otherwise agreed by the parties or ordered by the court, no disclosure may be made to anyone, including the judicial officer to whom the case is assigned, of any confidential dispute-resolution communication that reveals the parties’ dispute-resolution positions or the evaluating magistrate judge’s advice or opinions. Confidential dispute-resolution communications will not be admissible in any subsequent proceeding except as permitted by the Federal Rules of Evidence.
20-1723 Appeal (& 216-cv-02525-MMD-NJK)
CalMustang: Please replace my previous post, sticky this one. Thx.
(Relevant) UPDATE: below
Appellant: Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited (AMRN)
Appellee:
- West-Ward Pharmaceuticals International Limited (n/k/a Hikma Pharmaceuticals International Limited) and Hikma Pharmaceuticals USA Inc. (Hikma)
-Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. (Reddy)
CAFC; 20-1723 Appeal Available documents #:
4: DOCKETING STATEMENT (AMRN)
8: UNOPPOSED MOTION TO EXPEDITE BRIEFING AND ORAL ARGUMENT
13: DOCKETING STATEMENT (Hikma)
23: DOCKETING STATEMENT (Reddy)
30: APPELLANTS’ OPENING BRIEF
31: NOTICE OF CORRECTION OF APPELLANTS’ OPENING BRIEF
32: APPELLANTS’ CORRECTED OPENING BRIEF
33: ORDER]
34: ENTRY OF APPEARANCE / BIOTECHNOLOGY INNOVATION ORGANIZATION / Amicus curiae
35: ENTRY OF APPEARANCE / BIOTECHNOLOGY INNOVATION ORGANIZATION / Amicus curiae
36: ENTRY OF APPEARANCE / BIOTECHNOLOGY INNOVATION ORGANIZATION / Amicus curiae
37: ENTRY OF APPEARANCE / BIOTECHNOLOGY INNOVATION ORGANIZATION / Amicus curiae
38: ENTRY OF APPEARANCE / Aimed Alliance / Amicus curiae
39: BRIEF OF THE BIOTECHNOLOGY INNOVATION ORGANIZATION AS AMICUS CURIAE IN SUPPORT OF NEITHER PARTY
40: CERTIFICATE OF INTEREST / Aimed Alliance
43: BRIEF OF AIMED ALLIANCE AS AMICUS CURIAE IN SUPPORT OF APPELLANTS
44: NOTICE OF NON-COMPLIANCE (AIMED ALLIANCE)
47: CERTIFICATE OF INTEREST (Reddy)
49: BRIEF FOR DEFENDANTS-APPELLEES
50: APPELLANTS’ REPLY BRIEF
51: JOINT CERTIFICATE OF COMPLIANCE WITH FED. CIR. R. 33(a)
52: PLAINTIFFS-APPELLANTS’ STATEMENT OF COMPLIANCE WITH FEDERAL CIRCUIT RULES 11(d) AND 30(h)(1)(B)
53: CERTIFICATE OF COMPLIANCE WITH CONFIDENTIALITY RULES (Hikma)
54: CERTIFICATE OF COMPLIANCE WITH CONFIDENTIALITY RULES (Reddy)
55-1: NON-CONFIDENTIAL JOINT APPENDIX VOLUME I (APPX1-APPX1512)
55-2: NON-CONFIDENTIAL JOINT APPENDIX VOLUME II (APPX1567-APPX50688)
55-3: NON-CONFIDENTIAL JOINT APPENDIX VOLUME III (APPX50689-APPX111621)
DC; 216-cv-02525-MMD-NJK Available documents
Best,
G
H-
A follow-up ... Acc. to Markman:
Q: What is your view about the Astra Zeneca LP v. Apotex Inc. (Nos. 2009-1381, 1424 (Fed. Cir. Nov. 1, 2010) [see also: https://www.fr.com/news/skinny-labeling-and-the-inducement-of-patent-infringement-12-09-2010/]
A: HDGABOR – The Astrazeneca case did not address the issue of induced infringement of a patent covering an off-label indication. The Fish article by Terry Mahn suggests that certain reasoning from Astrazeneca’s opinion could, theoretically, be extended to hold generics liable for induced infringement of patents covering off-label indications. But more recent Federal Circuit cases, which are more on point, have held otherwise. See Takeda v. West-Ward, 785 F.3d 625 (Fed. Cir. 2015). There are always circumstances where a generic could be liable for induced infringement of a patent covering an off-label indication. But that typically requires conduct outside of the label, such as active promotion by Hikma or Dr. Reddy’s of the cardiovascular effects of generic Vascepa. But they are unlikely to do that.
Best,
G
Please do not mention me in the future ... I do not want to see your name and mine on the same screen ...
z-
judge Du stated that Vascepa was NOT a commercial success
In sum, the Court finds that Vascepa is a commercial success
c-
1) it will trigger gia, so? JT has been saying gia all along and you are not against gia either, right? You said it is a business decision between bo offering and gia
2) you then said high possibility for a new case loss against another generic in another DC
3) and additional comment on 2) any new case will take at least 30 month, right? This leads me to say patent litigation risk is always there,
I begin to wonder how did they manage to settle with apotex? No delay at all if any generic enter?
p-
there can not be many generics for the same drug
Outcome ...
Settlement: 0.00% (-100%)
Any settlement makes sense (if any) with vacatur only. But vacatur based on what? Singer's briefs? If it is good for vacatur it should be good for win ... But let's accept the vacatur (with settlement). It will trigger a GIA (maybe everywhere) because nobody will pay a reasonable amount for the US with existing possibility that somebody will win a new case (about MARINE) and the "pending" R-IT case ...
The settlement is not about money but about timing (market entry). Meanwhile I do not have the details of the TEVA and Apotex settlements, I am 99.9% sure Amarin could not settle an earlier entry for Hikma (or Reddy) than for T & A. (I mean If Hikma want anything before August 2029, T&A will get it also.)
Furthermore: any (most of the) business decision should be the best interest and is not the most safety. As I know not all of the court cases ended by settlement. Make it short: we bought Amarin shares and not government bonds ...
Remand: 0.01%
I see too many errors in the DC Order ... furthermore a remand will trigger - with 100% possibility, independently from the new DC Order - a new appeal.
Affirmed: <25%
It is a possibility. Prima facie vs totality is the weakest argument (and could be depends on the Judges). Weighting SCs and Kurabayashi (Apo-B) consideration by the USPTO is strong ... but a little bit depends on below / over 500 argument.
Reversed: >75%
Based on the 4 documents (DC Order, Opening and Reply Brief by Amarin, Generics Brief) I see it as the most likely outcome ... but I did not expect the DC Order ...
Best,
G
H-
Dunno ... it is an Nov. 1, 2010 ruling.
Was it used in any case as a basis / reference (since then)?
Was the same topic / issue ruled differently (since then)?
Best,
G
d-
Add to that the fact that Hikma gave financial projections to the World for a generic market stratospherically greater than the Marine label.
The reality … and a possibility (in case of loss at CAFC)
The reality
When a generic drug is approved by FDA, it receives a therapeutic equivalence code that is entered in the Orange Book beside the drug name to indicate whether it is approved as therapeutically equivalent to the pioneer drug (an “A” code) or not therapeutically equivalent (a “B” code). FDA considers drugs to be therapeutic equivalents if they are pharmaceutical equivalents and if they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling. Significantly, FDA states that “products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.”. Thus, under the current system, “skinny labeled” generics are designated by FDA and listed in the Orange Book as being fully substitutable for pioneers irrespective of their labeled uses.
HIKMA PHARMACEUTICALS USA INC (ICOSAPENT ETHYL) has “AB” TE code.
(The coding system for therapeutic equivalence evaluations is designed to allow users to determine quickly whether the Agency has evaluated a particular approved product (e.g., a particular strength of an approved drug) as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter).
A Drug products that FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, i.e., drug products for which: … (2) actual or potential bioequivalence problems have been resolved with adequate in vivo and/or in vitro evidence supporting bioequivalence. These are designated AB.)
In almost all cases, neither the prescribing physician, nor the pharmacist or the insurance carrier, has any idea what uses are approved on an A-rated generic label, because there is no compendium that tracks such information. Doctors typically write prescriptions for brandname drugs without reference to the indication or condition being treated, so there is no practical way for a pharmacist to determine (short of calling the doctor) what the drug is to be used for when the substitution decision is made.
In 14 states, pharmacists are required by law to substitute “equivalent” generic drugs for pioneer prescriptions unless the doctor specifies “brand only.” In 36 other states, pharmacists have the discretion to substitute equivalent generics unless the prescription is designated “brand only.” Forty-seven states allow generic drug substitution if requested by the patient, which, as a practical matter, means the decision to substitute is in the hands of the patient’s health insurance carrier, which charges much lower co-payment fees for generic equivalent drugs. As for how pharmacists determine whether a generic is equivalent to (and substitutable for) a brand-name drug, 30 states (including the District of Columbia) require use of the Orange Book, with several other states accepting the Orange Book rating system as an option. Three states publish their own formularies, and 18 others define “generic equivalence” essentially to include any generic that is A-rated by FDA. In other words, a generic drug that is A-rated by FDA will be substituted by pharmacies throughout the country and used by consumers regardless of the approved uses on the generic label.
HIKMA PHARMACEUTICALS USA INC (ICOSAPENT ETHYL) (and any gV in the future) is (will be) A-rated …
A possibility (???)
Using a patent-protected generic drug for a carved-out indication directly infringes the patent. Prescribing or dispensing the drug for such use indirectly infringes the patent. The problem, of course, is that no sensible pioneer drug company will pursue doctors, pharmacies or patients for patent infringement. Generic manufacturers, on the other hand, would make an ideal target, but historically they have managed to avoid litigation by making certain they do not actively promote their “skinny labeled” drugs for any patent-protected uses. Nevertheless, these drugs are placed on the market every day by generic manufacturers knowing they will inevitably be used by some consumers in an infringing manner. However, knowledge is not conduct, and without some manner of conduct, it has been difficult to charge generic drug manufacturers with the specific intent required to induce infringement. (The Federal Circuit’s holding in Warner-Lambert Co. v. Apotex Corp. that “where a product has substantial noninfringing uses intent to induce infringement cannot be inferred even when the [alleged inducer] has actual knowledge that some users of its product may be infringing the patent.”.)
There can be no disputing that direct infringement occurs whenever a generic drug is taken by or administered to consumers for a condition of use that is protected by patent. It does not matter what the prescribing physician intended, what the pharmacist is required to do or what the Orange Book therapeutic equivalence rating dictates. What matters is that “skinny labeled” drugs are being marketed by generic manufacturers with the knowledge that they will be used by some consumers in an infringing manner. The only question has been whether such infringement is being induced by the generic manufacturer’s conduct.
Astra Zeneca LP v. Apotex Inc. (Nos. 2009-1381, 1424 (Fed. Cir. Nov. 1, 2010) suggests that it may well be …
The Federal Circuit makes clear in AstraZeneca that liability for inducing infringement may be found where the evidence goes beyond a product’s characteristics, or the knowledge that it may be put to infringing uses, and shows “actions directed to promoting infringement.” It is sufficient, the court said, for a patent holder to show evidence of a manufacturer’s intent to induce infringement along with plans to market the drug knowing that such infringement will occur. In the case of a “skinny labeled” drug, the generic manufacturer appears to be in this same boat.
In AstraZeneca, the Federal Circuit equated labeling with conduct and rejected the defense that nonspecific label recommendations could not demonstrate specific intent. The court said it did not matter if the labeling contains only general recommendation – what matters is whether the labeling language would inevitably lead some users to practice the claimed method. This same reasoning would appear to hold true for “skinny labeled” generics, only here it is not the physical label that inevitably leads to infringement, but rather, the A-rating bestowed by FDA, published in the Orange Book and promoted by the generic manufacturers. In the end, the result is the same. The generic manufacturer effectively relies on an “extrinsic label” for its drug that will inevitably lead some users to practice the pioneer’s patent. It is this overall conduct that AstraZeneca seems to say is sufficient to show specific intent to induce infringement.
Best,
G
sources:
- Skinny Labeling and the Inducement of Patent Infringement
- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
- Orange Book Preface
C-
no insurance in europe. So no copays
20-1723 Appeal (& 216-cv-02525-MMD-NJK)
CalMustang: Please replace my previous post, sticky this one. Thx.
(Relevant) UPDATE: below
Appellant: Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited (AMRN)
Appellee:
- West-Ward Pharmaceuticals International Limited (n/k/a Hikma Pharmaceuticals International Limited) and Hikma Pharmaceuticals USA Inc. (Hikma)
-Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. (Reddy)
CAFC; 20-1723 Appeal Available documents #:
4: DOCKETING STATEMENT (AMRN)
8: UNOPPOSED MOTION TO EXPEDITE BRIEFING AND ORAL ARGUMENT
13: DOCKETING STATEMENT (Hikma)
23: DOCKETING STATEMENT (Reddy)
30: APPELLANTS’ OPENING BRIEF
31: NOTICE OF CORRECTION OF APPELLANTS’ OPENING BRIEF
32: APPELLANTS’ CORRECTED OPENING BRIEF
33: ORDER]
34: ENTRY OF APPEARANCE / BIOTECHNOLOGY INNOVATION ORGANIZATION / Amicus curiae
35: ENTRY OF APPEARANCE / BIOTECHNOLOGY INNOVATION ORGANIZATION / Amicus curiae
36: ENTRY OF APPEARANCE / BIOTECHNOLOGY INNOVATION ORGANIZATION / Amicus curiae
37: ENTRY OF APPEARANCE / BIOTECHNOLOGY INNOVATION ORGANIZATION / Amicus curiae
38: ENTRY OF APPEARANCE / Aimed Alliance / Amicus curiae
39: BRIEF OF THE BIOTECHNOLOGY INNOVATION ORGANIZATION AS AMICUS CURIAE IN SUPPORT OF NEITHER PARTY
40: CERTIFICATE OF INTEREST / Aimed Alliance
43: BRIEF OF AIMED ALLIANCE AS AMICUS CURIAE IN SUPPORT OF APPELLANTS
44: NOTICE OF NON-COMPLIANCE (AIMED ALLIANCE)
47: CERTIFICATE OF INTEREST (Reddy)
49: BRIEF FOR DEFENDANTS-APPELLEES
50: APPELLANTS’ REPLY BRIEF
DC; 216-cv-02525-MMD-NJK Available documents
Best,
G
g-
See sticky (and deduct 3 months from the latest)
Best,
G
icosapent ethyl - EMEA/H/C/005398 is not on June 22-25 meeting agenda (EMA CHMP)
- assuming 3 months was given for reply: no request of extension (of time to reply 120-day / March 26 letter)
- should be on agenda of the September meeting (as the latest). Opinion or List of outstanding issues (Day 180)
Best,
G
i-
What genius came up with the legislation that permits the courts to have jurisdication over the Gov't agency responsible for issuing patents?
r-
Thanks a bunch
r-
did Covington say it is 6 & Generics say it is 8? We know that Du concluded that it is 8.
Because if those 2 did say that, shouldn't Covington have explained why it is 6 and not 8?
In light of the statistically-significant differential effects reported between the EPA and control groups, a POSA would have attributed the reduction in Apo B to EPA.
Kurabayashi further reports a statistically significant reduction in Apo B levels in the EPA group of 6.9%. (Id. at 4-5.) With a p value of < .001, EPA’s effects on Apo B were highly significant. (Id.; see also ECF No. 367 at 737:1-23.) In contrast, Kurabayashi reports a non statistically significant 1.5% reduction in Apo B levels in the control group
r-
How do you explain Covington not hiring an expert to write a statistical analysis (during trial) that Bhatt's paper did (after trial)? Or was there no need to explain to Du back then WHY 2+2×2=6?